Protalix BioTherapeutics, Inc. (PLX) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary indicates a significant cash inflow from a strategic partnership, which is positive. However, the lack of detailed financial performance metrics, absence of shareholder return discussion, and mention of potential regulatory risks balance this positivity. The Q&A section does not provide additional insights, leaving some uncertainty. Overall, the sentiment is neutral, with no strong catalysts for a significant stock price movement.
Key Financial Performance
Revenue $25 million received during the quarter, representing a significant inflow for the company.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New Product Revenue: Received a $25 million payment during the quarter.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Forward-looking Statements: The earnings release and teleconference include forward-looking statements that are subject to known and unknown risks and uncertainties, which may cause actual results to differ materially from the statements made.
Regulatory Filings: Factors that could cause actual results to differ are described in Protalix's filings with the U.S. Securities and Exchange Commission, indicating potential regulatory hurdles.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Strategic Initiatives: During the quarter, we received a $25 million payment related to our strategic partnership.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Advisors Investor
Advisors LLC
BioTherapeutics Financial
CEO Director
CFO Treasurer
Cap Research
Director Senior
Division Vandermosten
Dror President
EDT lady
LLC Raghuram
LifeSci Advisors
Lifesci Advisors
Mr Dror
Mr LifeSci
President CEO
Protalix Senior
Raghuram Selvaraju
Relations Protalix
Research EDT
Secretary Lifesci
Selvaraju HC
Senior VP
Senior Vice
Treasurer Secretary
VP CFO
Vandermosten Zacks
Zacks Cap
conference host
host Mr
today Dror
PLX Transcript
Protalix BioTherapeutics, Inc. (PLX) Q1 2026 Earnings Call Transcript
Unknown5-13
The earnings call summary indicates a significant cash inflow from a strategic partnership, which is positive. However, the lack of detailed financial performance metrics, absence of shareholder return discussion, and mention of potential regulatory risks balance this positivity. The Q&A section does not provide additional insights, leaving some uncertainty. Overall, the sentiment is neutral, with no strong catalysts for a significant stock price movement.
Protalix BioTherapeutics, Inc. (PLX) Q4 2025 Earnings Call Transcript
Unknown3-18
The earnings call presented mixed signals. Financial performance showed a decrease in revenues and a net loss, but optimistic guidance and strategic initiatives like Elfabrio's rollout and PRX-115 development are promising. The Q&A highlighted potential market opportunities and competitive advantages, yet management's lack of specifics on timelines and targets raises uncertainties. The positive milestone payment and strategic focus on high unmet needs balance the negative financials and manufacturing issues. Overall, the sentiment is neutral due to balanced positives and negatives, with no market cap data to assess potential volatility.
Protalix BioTherapeutics, Inc. (PLX) Q3 2025 Earnings Call Transcript
Unknown11-13
The earnings call reveals mixed signals: increased R&D expenses and net loss improvement are positive, but unclear responses on revenue guidance and cash burn are concerning. The positive outlook for PRX-115's market potential and Elfabrio's potential EMA approval are offset by limited visibility on financial metrics. The Q&A section highlights uncertainties, with management's evasive answers potentially dampening investor confidence. Overall, the stock is likely to remain stable, resulting in a neutral sentiment.
Protalix BioTherapeutics, Inc. (PLX) Q2 2025 Earnings Call Transcript
Unknown8-14
The earnings call presents a mixed picture: increased revenues and a return to profitability are positive, but higher R&D expenses and unclear management responses in the Q&A raise concerns. While strong sales to Chiesi and improved net income are encouraging, the lack of guidance on key strategic areas and potential financial strain from increased R&D costs suggest a cautious outlook. The absence of a new partnership announcement or significant guidance changes also tempers enthusiasm, leading to a neutral sentiment prediction.
PLX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
